A. V. Zhavoronkova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
A. V. Zhavoronkova has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- A. I. Listratova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication - Anastasiya A. Sokolova
Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication - Anna A. Kudrjavtseva
Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication - Dmitry A. Napalkov
Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication - E. S. Bakhilina
I. M. Sechenov First Moscow State Medical University
1 shared publication - I. I. Ivanov
Pirogov Russian National Research Medical University
1 shared publication
Latest Publications
- Open Access
- 9 September 2024
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 20 (4) , 401-408
Nephroprotective and anticoagulant therapy in patients with atrial fibrillation and chronic kidney disease: real-world data
Aim. To assess the compliance of nephroprotective and anticoagulant therapy in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) with modern clinical guidelines.Material and methods. The study included patients with CKD in combination with AF and in sinus rhythm. Clinical characteristics were retrospectively assessed, as were the use of renin-angiotensin system inhibitors (RASi), statins, sodium-glucose transporter type 2 inhibitors (SGLT-2i) and oral anticoagulants (OAC).Results. A total of 464 patients (aged 66-80 years) were divided retrospectively in two subgroups — with and without AF. AF was detected in 210 (45.3%) patients. Patients from the subgroup with AF were significantly older (75 vs 72 years, p=0.001), more often had type 2 diabetes mellitus (T2DM) (28.6% vs 20.5%, p=0.042), coronary artery disease (CAD) (40.5% vs 30.7%, p=0.028) and chronic heart failure (CHF). (57.6% vs 22.8%, p2, p2, p=0.043). In patients with T2DM, SGLT-2i-2 was prescribed in 33.9% of cases, in patients with chronic heart failure with reduced ejection fraction (CHFrEF) — in 68.4% of cases. In 196 patients with AF, DOACs were prescribed, in 10 cases — warfarin.Conclusion. Most patients with CKD receive nephroprotective therapy with RASi and statins according to current KDIGO guidelines. A significant proportion of patients with CHFrEF receive SGLT-2i, but only a third of patients with T2DM and CKD received SGLT-2i therapy.
- 9 September 2024
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 20 (4) , 401-408
Open AccessNephroprotective and anticoagulant therapy in patients with atrial fibrillation and chronic kidney disease: real-world data
Aim. To assess the compliance of nephroprotective and anticoagulant therapy in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) with modern clinical guidelines.Material and methods. The study included patients with CKD in combination with AF and in sinus rhythm. Clinical characteristics were retrospectively assessed, as were the use of renin-angiotensin system inhibitors (RASi), statins, sodium-glucose transporter type 2 inhibitors (SGLT-2i) and oral anticoagulants (OAC).Results. A total of 464 patients (aged 66-80 years) were divided retrospectively in two subgroups — with and without AF. AF was detected in 210 (45.3%) patients. Patients from the subgroup with AF were significantly older (75 vs 72 years, p=0.001), more often had type 2 diabetes mellitus (T2DM) (28.6% vs 20.5%, p=0.042), coronary artery disease (CAD) (40.5% vs 30.7%, p=0.028) and chronic heart failure (CHF). (57.6% vs 22.8%, p2, p2, p=0.043). In patients with T2DM, SGLT-2i-2 was prescribed in 33.9% of cases, in patients with chronic heart failure with reduced ejection fraction (CHFrEF) — in 68.4% of cases. In 196 patients with AF, DOACs were prescribed, in 10 cases — warfarin.Conclusion. Most patients with CKD receive nephroprotective therapy with RASi and statins according to current KDIGO guidelines. A significant proportion of patients with CHFrEF receive SGLT-2i, but only a third of patients with T2DM and CKD received SGLT-2i therapy.